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Abstract 
 Optogenetics as developed by Dr. Karl Deisseroth and others has been a transformative technology in the 
area of neuroscience.  By stimulating genetically-modified neurons with visible light, modulation of the ionic 
conduction across the cell membrane can be achieved with very high specificity and precise temporal control.  Despite 
the major influence of this technique, its scope is limited by its invasive nature and its lack of stimulation depth.  
Visible light is unable to penetrate deeply into biological soft tissue and has even greater difficulty passing through 
hard tissues such as bone.  Therefore, to deliver the light to the nerves, a window in the subject’s skull must be 
surgically made and a light probe, either LED or laser, is inserted near the area of interest.  At this point, the surface 
of the cortex is available for stimulation as visible light is interacting with the soft tissue of the brain.  Recent grants 
have been awarded to groups that investigate ways to eliminate the need for the invasive surgery by introducing 
fluorescence emitting nanoparticles into the brain.  Through stimulation of these particles with infrared light, 
subsequent visible fluorescence occurs.  Hence, the stimulating light source can be moved into the brain and 
functionally targeted to the genetically-modified cells.  However, despite the incrementally improved depth available 
with IR stimulation, much of the brain remains out of reach. To address these limitations, we propose two new methods 
for optogenetic stimulation.  The first is x-optogenetics, which uses visible light-emitting nanophosphors stimulated 
by focused x-rays.  This idea is not new but the application to optogenetics is novel.  X-rays can penetrate much more 
deeply than infrared light and could allow for nerve cell stimulation in any part of the brain.  In this paper, we discuss 
the feasibility and possibilities of such a method by describing the advances in nanomaterials, x-ray focusing, and x-
ray sources.  Also, we discuss concerns when dealing with x-rays such as radiation dosage. Through the use of 
quantities and assumptions backed by recent literature, manufacturer specifications, and personal correspondence, a 
full feasibility analysis of x-optogenetics is completed.  The second proposed method we explore is u-optogenetics, 
which is the application of sonoluminescence to optogenetics. Such a technique uses ultrasound waves instead of x-
rays to induce light emission, so there would be no introduction of radiation.  However, the penetration depth of 
ultrasound is less than that of x-ray.  The key issues affecting feasibility are laid out for further investigation into both 
x-optogenetics and u-optogenetics. 
 
1. Introduction 
 After a transformative technology is invented, there is often a period of improvements and optimizations that 
expands the reach of the technology.  Optogenetics, an incredibly innovative technology that allows for deep insight 
in the field of neuroscience and neuropathology, falls into this category of transformative technologies.  Since its 
introduction into mainstream science less than twenty years ago, a number of teams have adopted the technique to 
study the roles of various neurons in disease states such as Parkinson’s, epilepsy, and depression1.  However, these 
applications are limited in their scopes because of the invasive nature and depth limitation of optogenetics.  There is 
a critical and immediate need to improve optogenetics for deeper and non-invasive applications. 
 In this paper, we will briefly review the optogenetics technique focusing on the areas that need improvement, 
and introduce two possible enhancements that seek to eliminate invasiveness and overcome depth limitations. One of 
our proposed techniques takes advantage of the recent advances in both nanomaterials and x-ray optics.  Through this 
unique combination, x-optogenetics can deeply target nerves without any surgical intervention. The other method aims 
to take advantage of methods previously demonstrated in vivo that enable ultrasonic-induced luminescence without 
radiation2.  Both methods offer transformative improvements to what is already a powerful technology.  
 
2. Methodology and Results 
2.1. Optogenetics 
Optogenetics refers to the technology that uses visible light to trigger proteins that modulate membrane 
potentials in neuronal cells through excitatory or inhibitory membrane currents3.  This ability of controlling neuronal 
cells has proven instrumental in preclinical studies and holds enormous potential for the treatment of diseases such as 
Parkinson’s, depression, and vision-impairments1.  However, the current techniques used for optogenetic control 
remain too invasive for clinical applications.  These techniques are briefly described below to describe the motivation 
behind our innovative ideas for advancing their efficiency and scope. 
Created by Karl Deisseroth, the original form of optogenetics uses channelrhodopsin2 (ChR2) to induce 
excitatory potentials in transfected neurons of small animals.  ChR2 is a protein found in green algae that becomes 
permeable to cations in the presence of blue light.  Deisseroth rationalized that ChR2 could be used in neurons since 
ion channels are a main contributor in electrical signal transduction in the brain. Since then, the technology has allowed 
researchers to target specific areas of the brain and study how modulated neuron firing affects downstream behaviors 
and cellular processes4,5. 
Optogenetics is performed in multiple steps: first, specified neuronal cells are transfected with DNA encoding 
for light-sensitive ion channels such as ChR2, halorhodopsin (NphR), and archeorhodopsin (Arch).  Upon expression 
of these proteins, scientists surgically implant a light fiber into the organism’s brain so light at the stimulating 
wavelengths can directly irradiate neurons and modulate their membrane current. Membrane current modulation 
comes in two forms that depend on the ions to which the channel becomes permeable in its open state.  The cation 
specific channels lead to membrane depolarization (excitatory) and the anion specific channels cause the membrane 
to hyperpolarize (inhibitory)3.  
In this way, the membrane current is directly controlled by a light source which is currently in the form of 
either a laser or a LED.  Both sources have limitations. Lasers are very costly and have some light loss.  On the other 
hand, the light from a LED is spread out and is not a straight beam, so it cannot be accurately targeted as laser can6–9.  
It should be noted that current practice of optogenetics is performed on a macroscopic scale.  For example, ChR2-
expressing cells have been activated by a 470-490 nm light in power range 1-20 mW/mm2 and pulse duration 5-100 
ms.  This type of stimulation results in ChR2-channel driven membrane current that peaks around -9 pA/pF6–8,10.  In 
these experiments, the studied tissue is flooded with light and any cell within a few millimeters of the source that is 
expressing light-sensitive ions channels will have modulated membrane currents that may lead to distinct network 
and/or behavioral changes.  The proposed x-optogenetic and u-optogenetic techniques shift the scale from the 
macroscopic to a microscopic or even nanoscopic level of control.  This will become more apparent in the following 
sections and the feasibility analysis. 
Because of the invasive nature or limited penetration of LEDs and laser sources, researchers are trying to 
find light sources that do not require surgically implanting a probe into an organism and that deliver light more deeply.  
For example, Dr. Gang Han uses near infrared radiation to excite upconversion nanoparticles (UCNPs).  After 
excitation these nanoparticles will emit photons of light whose wavelengths can be customized based on the particle 
chemistry.  These emissions are then used to modulate the membrane current just as the light sources described above.  
This method offers a unique and less invasive approach to optogenetics as deeper levels of the brain can be mapped 
due to the deeper penetrating abilities of infrared light11.  Table 1 lists a number of these light-emitting nanoparticles 
(nanophosphors) which have been reported in the literature and may have utility in this regard.  Despite this 
incremental improvement to the optogenetic approach, infrared (IR) light has its limitations as well.  First, IR 
penetration through the skull has been shown to be between 4 and 10% of the initial intensity12.  Furthermore, IR light 
at 868 nm only penetrates brain tissue around 2.5 mm13, which can only gain access to a fraction of human cortical 
neurons as the human cortex thickness is typically on the range of 2 to 5.5 mm14.  We believe that these challenges 
can be addressed through the use of x-rays, rather than infrared light, to stimulate nanophosphors.  X-rays are capable 
of very deep penetration and can also be precisely focused as is discussed below.  Due to the radiation dose introduced 
by x-rays, we also explore the possibility of ultrasonic stimulation of air bubbles that emit light via sonoluminescence. 
This technique would not introduce radiation to the subject, but the penetration depth would not be as high as that of 
x-ray stimulation methods.   
 
2.2. Key Elements for X-optogenetics 
2.2.1. X-ray Excitable Nanophosphors  
 To perform x-optogenetics, the x-rays must be converted to visible light; therefore, x-ray excitable 
nanophosphors must be used. The nanophosphors need to be biocompatible and emit light at wavelengths that properly 
activate the light sensitive ion channels. This idea was recently used as the basis of a patent application, though it 
simply describes using x-ray excitable nanophosphors for general “control of light-sensitive bioactive molecules” 
without any quantitative analysis of feasibility or radiation dose implications15.  A literature survey of nanophosphors 
verified that a large number of nanophosphors can be readily produced with tunable emission, absorbance, and 
solubility properties. Table 1 shows a large number of nanophosphors with emission maxima in the visible domain.  
With regards to their excitation spectra, however, two distinct types of nanoparticles can be seen: up-conversion 
nanoparticles (UCNPs) and UV/x-ray excitable nanoparticles.  As stated above, UCNPs emit visible photons during 
exposure to long wavelength infrared radiation, while the UV/x-ray excitable particles emit visible photons during 
exposure to short wavelength UV/x-ray radiation.  It should be noted that particles in the same conversion class are 
often doped with similar ions.  For example, UCNPs often contain Yb3+, Ln3+, or Er.  On the other hand, particles 
sensitive to the shorter wavelength radiation often contain Cr3+, Eu3+, or Tb3+. 
 Of the reported nanophosphors, most have the excitation wavelength in the range from 147nm to 980nm.  
There are five nanophosphors in the survey with an excitation wavelength of 980nm all of which are upconverting 
nanoparticles (UCNPs). X-rays have a wavelength range from 0.01 to 10 nm16 and therefore cannot efficiently excite 
these nanophosphors.  However, the particles with the base chemistry of Gd2O2S and LiGa5O8 have been shown to 
absorb light in both the UV and x-ray ranges. Additionally, these particles have been doped with Cr3+, Eu3+, or Tb3+.  
Other particles in the survey also utilize these dopants and may also prove to be useful for x-ray excitation.  Further 
research should generate optimal nanophosphors for x-optogenetics. 
 The results from the literature suggests that there are a number of techniques available to improve the 
nanophosphors that can be used for x-optogenetics, especially in the areas of solubility, conversion efficiency, 
emission, size, and targeting.  For example, Table 1 includes nanophosphors that emit light across the visible light 
spectrum and into the NIR range with the shortest wavelength emitted at 450 nm and the longest at 800nm. The 
emission wavelength is a result of the chemical formula of the nanophosphor and the compound with which it is 
doped. For example, NaYF4 doped with Eu3+ has an emission wavelength of 592 nm while NaYF4 doped with Tb3+ 
has an emission wavelength of 545 nm. The ability to alter a nanophosphor’s emission wavelength by changing the  
    
Table 1. Survey of nanophosphors in the literature. Italicized entries represent nanophosphors which may be useful for x-optogenetics 
as Eu3+ and Tb3+ are common dopants for x-ray excitable nanophosphors.  Not all of these particles reported x-ray induced fluorescence.  
(PEG – polyethylene glycol, PAA – poly(acrylic acid), PGA – polyglycolic acid, PEI – polyethylenimine, DSPE-PEG-COOH – 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)]). 
 
Formula Source 
Emission 
Maximum 
(nm) 
Excitation 
Wavelength 
(nm) 
Conversion 
Efficiency 
(%) 
Size 
(nm) 
Dispersible Toxicity 
Gd2O2S:Eu3+ (Tb3+) 17–20 620 (545) <310 15 50-300 
Yes, PGA-
PEG 
Low 
Y2O3:Eu3+ 21–23 610 <310 80 10-50 Yes -- 
LiGa5O8:Cr3+ 24,25 716 <310 -- 50-150 Yes, PEI Low 
Gd2O2S:Yb(8),Er(1) 26 500-700 980 25 4 µm Yes Low 
NaMF4 :Yb3+/Ln3+ 27 510-560 980 -- 60 
Yes, 
DSPE-
PEG-
COOH 
Low  
La(OH)3:Eu3+ 28 597, 615 280 -- 3.5 Yes, PEG Low 
NaYF4:Yb/Er 29 
520, 540, 
654 
980 -- 33 ± 1 Yes, citrate -- 
NaYF4:40%Eu3+ 30 592 394 -- 28 Yes, PAA Low 
NaYF4:40%Tb3+ 30 545 368 -- 28 Yes, PAA Low 
cit-NaLuF4:Yb,Tm 31 800 980 -- 25 
Yes, citric 
acid 
Low 
Ba2SiO4 32 505 350 38.6 40-50 -- -- 
Na2Sr2Al2PO4F9: 
Eu3+ 
33 593, 619 393 -- 35.26 -- 
Non-
toxic 
materials 
BaMgAl10O17:Eu2+ 34 450 147 -- 
62, 85, 
115, 
160, 
450 
-- -- 
Sr2CeO4 35 467-485 240-360 -- 45 -- -- 
LiCaPO4:Eu2+0.03 36 476 375 
Quantum 
Efficiency: 
53.7, 67.6 
 Yes, PEG-P -- 
PEG-Er-Y2O3 37 660 980 -- 30-60 Yes, PEG Low 
GdVO4:Eu3+ 38 620 330 -- 6 Yes Low 
chemical formula or the compound with which it is doped should be beneficial in optimizing nanophosphors for x-
optogenetics.  Hybrid doping schemes may also allow for more tailored emission spectra. 
 The conversion efficiency is the ability for the nanophosphors to convert x-ray energy to visible light energy.  
This value was not expressed for many of the nanophosphors, though it remains an important consideration for x-
optogenetic applications.  When choosing a nanophosphor for x-optogenetics, the conversion efficiency should be as 
high as possible to reduce the amount of time and x-ray dose to which the subject is exposed.  It is underlined that we 
consider x-ray stimulation feasible and safe, given the extensive research on x-ray luminescence imaging in preclinical 
applications39. 
 When considering x-optogenetics for neuronal intervention, the size distribution and coating of the 
nanophosphors is important for penetration of the phosphors across the blood brain barrier (BBB) to gain access to 
the cells in the brain.  Size distribution of particles targeted outside of the central nervous system do not need to be as 
small, but should still be optimized for maximum bioavailability.  Studies using polysorbate-coated nanoparticles 
showed maximum passage through the BBB for nanoparticles under 100 nm in diameter40. With the sizes of the 
nanophosphors in the survey between 10 nm and 1 µm and recent advances in nanotechnology, it should be feasible 
to obtain nanophosphors with an appropriate size distribution for a range of x-optogenetic applications41. 
In addition to size, the ability for the particles to be soluble or colloidal in water is a critical property of the 
nanophosphors as this should add to their biocompatibility. A number of surface coatings including polyethylene 
glycol (PEG) and other forms of hydrophilic polymers were used to help solubilize or suspend the surveyed particles 
in aqueous solutions.  These types of coatings could be used for the nanophosphors to facilitate x-optogenetics.  These 
coatings can also have a profound effect on the ability of the particles to cross the blood brain barrier40. 
 
2.2.2. Nanoparticle Targeting 
One important issue with x-optogenetics is the placement of the light sources that will be used to generate 
membrane current in the target neurons.  The proximity of these nanophosphors in relation to the light-sensitive ion 
channels must be within a few millimeters as power density is reduced by >90% after 1 mm for all wavelengths of 
visible light42.   
One way of combating this light loss through tissue would be to directly target the light-sensitive ion channels 
through functionalization of the nanoparticles.  Several groups have demonstrated the ability to conjugate small 
peptide sequences or antibodies that can be used to enhance cellular uptake or adhesion to the cellular membrane43–45.  
Using similar methods, the nanophosphors could be functionalized to specifically bind to the light-sensitive ion 
channels that are on the target neurons.  In this way, the proximity issue between the light-sensitive ion channels and 
the light sources can be minimized and the light loss due to tissue absorption mitigated. 
 
2.2.3. X-ray Focusing 
Targeting the genetically-modified neurons through functionalization of the nanophosphors will provide the 
first level of control for neuron activation.  A second level of control comes from the ability to focus the x-rays through 
the use of a polycapillary lens, a zone plate, or another similar means such as a grating.  In addition to enhanced control 
over the neuronal activation, focused x-rays will result in less bulk x-ray dose to the patient which is always of high 
concern when dealing with ionizing radiation. 
A polycapillary lens focuses x-rays in the form of an intense microspot using an array of glass micro-
capillaries.  The size of the focal spot can get as low as 5 µm46.  However, for single neuron targeting focal spots of a 
few 100 µm may be more applicable. Conventional polycapillary lenses have a working energy range of 0.5 to 30 
keV.  These can be described as soft x-rays and more easily absorbed by the brain tissues.  Also, polycapillary optics 
has recently been made for focusing of higher energy x-rays up to 60 keV, although transmission through these lenses 
is <5% at energies higher than 5 keV47. 
Excitation of x-ray excitable nanophosphors using the same mechanisms has been previously proposed and 
simulated by our group48.  As described for x-ray fluorescence computed tomography (XFCT) applications, the x-ray 
intensity distribution in biological soft tissues can be approximated with inverse distance weighting.  In this 
approximation 𝐼(𝒓) = 𝐼0𝑊(𝒓, 𝒓0)/‖𝒓 − 𝒓0‖
2, where r0 is the vertex of the double cones, I0 is the intensity of the x-
ray source, and W(r,r0) is the aperture function of the double cones at the vertex r0.  For accurate membrane current 
modulation of the target neurons, the initial intensity of the x-ray source can be adjusted so that the nanophosphors 
near r0 will receive enough x-ray energy to emit a sufficient number of light photons to open the ion channels. This 
real-time adjustment is also dependent on the location of the target neurons as well as the size and fluorescence 
conversion efficiency of the nanoparticles. 
Focusing x-rays can be more precise through the use of a Fresnel zone plate (FZP).  FZPs are micro-fabricated 
from a soft metal such as gold or nickel, and modulate either amplitude or phase-shift of incoming x-rays.  These 
modulations result in a wave diffraction and constructive interference at a focal point49.  One consideration is that 
zone plates are typically used for synchrotron radiation produced x-rays.  Similar to the polycapillary lens, zone plates 
are most effective for x-rays with lower energy levels (5-8 keV)49.  All things considered, the polycapillary lens may 
be initially the best option for x-optogenetics.  
 
2.2.4. X-ray Carbon Nano-Tube (CNT) Sources 
Another key aspect of optogenetics that must be addressed by x-optogenetics is the delivery of light in pulses 
5 – 100 msec in duration.  With the light emitted from the nanophosphors as they are excited by x-rays, the pulsation 
must come from the x-ray source itself.  Conventional tubes emit x-rays under 10 – 500 mA current and require several 
minutes for warming-up before emission.  Achieving a sufficient pulsing emission rate will not be possible with such 
a source.  Fortunately, recent progress has been made on the development of carbon-nanotube field-emission cathodes 
that can produce soft x-rays at about 8 keV and are capable of pulsing at high rates for x-optogenetics research and 
application50. 
 
2.2.5. X-ray Dose 
 With the involved ionizing radiation for x-optogenetics, it is important to quantify the delivered radiation 
dose during a procedure.  While everyone is subject to a baseline effective dose of about 3 mSv a year, increased 
levels of radiation exposure occur as a result of x-ray, CT, and/or PET imaging exposure.  The effective dose from 
such a scan can range anywhere from 0.001 mSv to 25 mSv.  These values depend on the region of exposure, type of 
radiation, and type of scan.  For x-ray related scans, a highest effective dose administered is around 10 mSv51.  We 
will use this number as the highest effective dose permissible for x-optogenetics protocols in the following feasibility 
analysis. 
 
2.3. X-Optogenetics Feasibility and Safety Analysis 
 Table 2 summarizes the requirements used for the various light-sensitive ion channels in past studies.  As 
stated previously these techniques take a macroscopic view on the requirements of optogenetics.  When considering 
the requirements needed to perform x-optogenetics, a micro/nanoscopic scale must be used and converted to 
macroscopic changes.  The nanophosphors must be excitable with x-rays, be biocompatible, and have a high 
conversion efficiency.  Depending on the nanophosphors used, the x-ray dose may be able to be adjusted. In any case, 
the nanophosphors should emit visible light or similar photons that can be used for optogenetics.  A CNT, polycapillary 
lens, Fresnel zone plate or a similar component should be used to deliver x-rays. 
 
Table 2. X-optogenetic overview for multiple light-sensitive ion channels.  Included in this table are approximate sizes of the channels which 
helps validate close proximity of nanophosphors and channels after targeting.  Furthermore, nanoparticles that can be used for targeting the 
ion channels are specified.  
Ion Channel Channelrhodopsin 2 
(ChR2) 
Halorhodopsin 
(NphR) 
Archeorhodopsin 
(Arch) 
Channel Mass 60-70 kDa 52 30 kDa 53 28 kDa 54 
Minimum Channel Radius 
(assuming spherical) 
2.58-2.72 nm 55 2.05 nm 55 2.00 nm 55 
Intensity 2-20 mW/mm2 56 7.9 mW/mm2 57 76.1 mW/mm2 57 
Wavelength 488 nm 56 532 nm 57 532 nm 57 
Pulse Train 5 msec, 40 Hz 56 15 sec illumination 57 15 sec illumination 57 
Depolarizing/Hyperpolarizing Depolarizing Hyperpolarizing Hyperpolarizing 
Possible Nanophosphors BaMgAl10O17:Eu2+ 
LiCaPO4:Eu2+0.03 
Gd2O2S:Tb3+ 
(combination doping?) 
Gd2O2S:Tb3+ 
(combination doping?) 
Hardware 
Specifications/Involved 
Components 
SOURCE: Carbon Nanotube (peak ~8 keV, pulsing capability) 
FOCUSING ELEMENT: polycapillary lens OR Fresnel zone plate 
 
 
Assuming a maximum effective radiation dose of 10 mSv, a theoretical calculation of power emitted from 
the nanophosphors can be done.  For x-ray radiation, a Sievert (Sv) is defined as 1 Joule (J) of energy per kilogram 
(kg) of tissue.  By definition, 1 J is equal to 6.24 E 12 MeV58.  Furthermore, the density of brain tissue is given in the 
literature to be 1.04 g/cm3 59.  Using these relationships, the following conversion can be done. 
 
0.010 𝑆𝑣 (
1
𝐽
𝑘𝑔
1 𝑆𝑣
) (
6.24𝐸12 𝑀𝑒𝑉
1 𝐽
) (
0.00104 𝑘𝑔
1 𝑐𝑚3
) (
1 𝑐𝑚
10 𝑚𝑚
)
3 
= 6.4896𝐸4 𝑀𝑒𝑉/𝑚𝑚3 
This conversion is the approximation of x-ray energy absorbed per cubic millimeter of brain tissue.  Then, 
let us approximate the number of nanophosphors in a cubic millimeter of brain tissue.  Chen et al. performed in vivo 
imaging studies and the effective nanophosphors concentration used was 133 µg/cm3 18.  According to the 
manufacturer, there are about 3.25 x 1013 nanophosphors per gram or 3.25 x 107 per microgram.  Under the assumption 
that the nanophosphors are distributed at a concentration of 133 µg/cm3 of tissue, a mass ratio can be calculated to be 
about 1 gram of nanophosphors to 8000 grams of tissue.  This ratio will be used to approximate the amount of the 
absorbed energy that will be converted to visible light photons.    The conversion efficiency is dependent on the 
nanophosphors chosen for a particular application.  The Gd2O2S:Tb3+ nanophosphors have an emission wavelength of 
545 nm, being close to wavelengths at which halorhodopsin and archeorhodopin are sensitive.  Furthermore, Chen et 
al. have reported that the conversion efficiency of these particles to be about 60,000 visible photons per MeV of 
absorbed x-ray energy18.  Using these assumptions the following conversions can be done. 
6.4896𝐸4
𝑀𝑒𝑉
𝑚𝑚3
(
1 𝑔 𝑁𝑃
8000 𝑔 𝑇𝑖𝑠𝑠𝑢𝑒
) (
60000 𝑝ℎ𝑜𝑡𝑜𝑛𝑠
𝑀𝑒𝑉
) = 4.8672𝐸5 𝑝ℎ𝑜𝑡𝑜𝑛𝑠/𝑚𝑚3 
4.8672𝐸5
𝑝ℎ𝑜𝑡𝑜𝑛𝑠
𝑚𝑚3
 (
1000 𝑚𝑚3
133 µ𝑔
) (
𝜇𝑔
3.25𝐸7 𝑛𝑎𝑛𝑜𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑟𝑠
) =
0.11 𝑝ℎ𝑜𝑡𝑜𝑛𝑠
𝑛𝑎𝑛𝑜𝑝ℎ𝑜𝑠𝑝ℎ𝑜𝑟
 
 Less than one photon per nanophosphor is not enough photons to activate ChR2.  However, two of the 
assumptions can be altered to greatly enhance the number of photons per nanophosphor.  The first is the phosphor 
diameter.  The nanophosphor mass used in the equation was for 50 nm diameter nanophosphors.  Simply by increasing 
the nanophosphor diameter by a factor of 3 (150 nm), the nanophosphor mass will be increased by 27 times (33), 
assuming the material density is constant.  This increase boosts emission to 3 photons per nanophosphors.  Further 
improvement can be achieved by increasing the conversion efficiency of the nanoparticles.  The current conversion 
factor (60,000 photons/MeV) is only 15% efficient as there is enough energy to generate ~400,000 visible photons 
(496 nm) in one MeV.  Therefore every 5% increase in efficiency is equal to an increase of 20,000 photons.  With 
both of these adjustments considered, phosphors with a diameter of 150 nm and a quantum efficiency of 50% will 
emit more than 10 photons per nanophosphor under the acceptable x-ray dose.  
The second part of the feasibility analysis is the number of light photons needed to open the light-activated 
ion channels.  To approximate this number, an understanding of the gating mechanism in the proteins is necessary.  
The light-sensitive moiety of rhodopsins such as ChR-2 and halorhodopsin, is retinal.  Retinal is a covalently bound 
derivative of Vitamin A that isomerizes under light excitation.  According to Hegemann and Mӧglich, the sensitivity 
of channelrhodopsin is defined in part by the quantum efficiency of retinal.  This is described as the likelihood of the 
chromophore to isomerize after absorption of a single photon of light.  This efficiency falls between 30-70% in 
rhodopsins60.  With this in mind, an ion channel will need between 1.5 and 3 photons of absorbed light to isomerize 
the retinal molecule and trigger an opening in the channel.  As calculated above, by increasing the radius of the 
particles alone, sufficient numbers of photons can be generated by the delivered x-ray dose to open the ion channels. 
 
2.4. U-optogenetics via Sonoluminescence 
 Sonoluminescence was first discovered in 1934 as a consequence of air bubbles in a photo-developing 
solution that emitted short bursts of light when subjected to ultrasonic waves61. The principle of this effect is that 
within these air bubbles, there are collisions between free electrons and ions, and when the air bubbles collapse, all 
these collisions result in thermal bremsstrahlung radiation, which is released as a short burst of light62. Studies have 
shown that the sonoluminescence effect can be enhanced by the introduction of a chemiluminescent agent, such as 
fluoresceinyl Cypridina luminescent analog (FCLA), which reacts with oxygen free radicals in air bubbles2. Under 
ultrasonic waves with a pressure of 200 kPa, FCLA molecules dissolved in water were reported to emit strong 
chemiluminscence at a peak wavelength of 532 nm with an intensity of 12580 photons cm-2 s-1 in a mouse model2. 
This characteristic presents an ideal emission wavelength for use in optogenetics, namely u-optogenetics. FCLA would 
need to be targeted to ion channels in a similar method to what was previously mentioned for x-ray excitable 
nanophosphors. When subjected to ultrasound waves, the collapsing air bubbles would emit bursts of light to trigger 
the subsequent stimulation of ion channels that absorb photons at 532 nm, including halorhopsin and archeorhodopsin.   
Figure 1A illustrates the use of sonoluminescence to stimulate the ion channels. Under these conditions, 
sonoluminescence provides an alternative excitation pathway in optogenetics. The advantage of ultrasound over x-ray 
methods is that no radiation dose would be introduced to the patient. However, there is greater attenuation of ultrasonic 
waves in tissue and bone as compared to x-rays, so penetration depth would be limited. By using low frequency 
ultrasound waves, penetration depth can be maximized. For ultrasound waves with a frequency of 1 MHz, the 
penetration depth in bone is approximately 0.3 cm; at a wave frequency of 100 kHz, the penetration depth would 
increase to approximately 3 cm63. Further, a new study has been reported that may enable even greater penetration 
depths for ultrasound through the skull by use of acoustic complementary metamaterials that can cancel out aberrating 
layers in bone64.  
The feasibility of u-optogenetics hinders mainly on the ability of FCLA, or another chemiluminscent agent, 
to target ion channels directly. Ultrasonic stimulation provides a non-invasive way to stimulate light emission with 
greater depth than traditional optogenetics. U-optogenetics also has an advantage over x-optogenetics by not 
delivering radiation, but it does not equal the penetration distance of x-ray techniques. 
 
3. Discussions and Conclusions 
Putting the pieces together, x-optogenetics seems to be a promising approach beyond the currently accepted 
optogenetic techniques.  Figure 1B illustrates the combination of the key elements needed for x-optogenetics as 
described in the Methodology and Results section.  By replacing the light sources in the form of lasers or LED with 
x-ray excitable nanophosphors, the issues of invasiveness and depth-limitedness of optogenetic stimulation can be 
addressed.  Through functionalization of the nanoparticles, a desirable targeting capability can be achieved that will 
allow for accumulation of the nanophosphors near the light-sensitive ion channels.  When choosing the 
nanophosphors, those with high energy conversion efficiency will be preferred as they will work with lower x-ray 
dose, given the minimum power emission for cell stimulation.  Furthermore, size distribution of nanoparticles will 
also affect the dose needed to achieve sufficient visible light emission.  Polycapillary lenses or zone plates can be used 
to focus x-rays onto altered cells.  The x-ray flux will directly affect the density of the emitted light.  Through the use 
of a carbon nano-tube x-ray source rather than a conventional source, a high level of temporal control can be 
implemented over x-ray excitation, inducing luminescence pulses from the nanophosphors at suitable frequencies and 
duty cycles. 
X-optogenetics is a feasible idea since it uses a safe x-ray dose to excite nanophosphors allowing photon 
emissions that will be able to reach and activate ion channels in targeted, light-sensitive ion channels.  As previously 
stated, there will be enough photons to activate the ion channels if the radius and/or conversion efficiency of the 
nanophosphor is increased. It should be noted that increasing the radius of the nanophosphor will lead to additional 
considerations.  For example, the nanophosphor must be small enough to pass through the blood brain barrier (BBB); 
therefore, increasing the nanophosphor radius could decrease the nanophosphor penetration into the BBB.  
Optimization of size distribution, particle emission, and BBB penetration will be a key consideration moving forward 
with x-optogenetics.  If it is determined that the nanophosphor’s radius is increased by more than what would pass 
through the BBB, x-optogenetics could also be applied to other regions of the body65. 
Additionally, the importance of targeting x-ray excitable nanophosphors to the ion channels should be noted.  
The closer the nanophosphors are to the ion channels, the more photons there will be able to activate them.  Therefore, 
the nanophosphors should be targeted to the ion channels as closely as possible.  It is likely that only a small number 
of channels will be directly targeted by the nanophosphors relative to the number expressed in a given cell.  This may 
have a substantial impact on the ability for x-optogenetics to have macroscopic and behavioral effects. 
In most optogenetic studies, the light stimuli are delivered in sub-second pulse trains over relatively longer 
periods.  We have discussed the importance of using the CNT for having millisecond control over the x-ray delivery, 
however, in the feasibility analysis the whole dose is assumed to be used in a single pulse.  Clearly, administering a 
x-ray pulse train of 10 mSv each greatly increases the total effective dose, putting the subject at risk for radiation 
poisoning.  However, a recent study has looked into the inhibitory effects of ChR2-based mutants after a single light 
pulse66.  These variants can have effects that outlast the light stimulus.  Therefore, x-optogenetics remains a feasible 
option for these variants since a single x-ray dose resulting in a single light stimulus will cause lasting inhibition in 
the target neurons. 
U-optogenetics via sonoluminescence provides a second alternative method to stimulating ion channels 
without the need for implanted light sources. This technique differs from x-optogenetics in that it relies on ultrasound 
waves as the medium for inducing light emission, instead of x-rays, and therefore does not introduce a radiation dose. 
The penetration depth of u-optogenetic techniques would not be as high as in x-optogenetic methods, but 3 cm 
penetration depth through the skull using 100 kHz ultrasonic waves would still be a substantial advantage over 
traditional optogenetics. Sonoluminescence would be enhanced by a chemiluminescent agent such as FCLA, which 
would emit bursts of light from air bubbles collapsing under ultrasonic pulses. Targeting of FCLA to ion channels 
provides a means for direct stimulation, but this mechanism remains an area of further investigation.  Furthermore, u-
optogenetics will not have the pulse-train limitations as radiation dose is not an issue for this technique. 
Without the use of a light probe, x-optogenetics and u-optogenetics turn optogenetics into a less invasive and 
more applicable research tool. The decreased invasiveness puts optogenetics one step closer to being applied to 
subjects other than rodents.  Additionally, it makes optogenetics a less time-consuming and more ethical process since 
researchers no longer need to surgically drill into the skull of their subjects.  Moreover, the ability for x-optogenetics 
and u-optogenetics to be performed deeply into the tissue would allow researchers to study parts of the brain that 
current practice of optogenetics does not allow.  This would create a grand opportunity to learn and explore parts of 
the brain that have yet to be explored. 
  
  
 
Figure 1.  A.) Schematic of U-optogenetics that heuristically demonstrates use of ultrasound to induce sonoluminescence and modulate 
membrane potential.    B.) Schematic of X-optogenetics showing the use of a CNT source as well as a polycapillary lens for x-ray focusing 
into a double-cone geometry.  CNT source schematic was adapted from Zhang et al67.  Brain and neuronal cell images were sourced from 
Microsoft clipart68,69. 
    
  
  
  
  
       
    
    
  
  1- Carbon nanotube cathode emits electrons which are focused 
onto the anode through a gate and focusing electrode. 
2- X-rays emitted from the anode are focused into the tissue 
through a polycapillary lens.  The max dose for x-
optogenetics is assumed to be 10 mSv.  Any unabsorbed 
radiation will be collected by a detector or x-ray stop. 
3- Nanophosphors are tagged to the light sensitive ion channels.  
Those NPs which are irradiated by the focused x-ray can emit 
up to 10 photons of light.  
4- Light-sensitive ion channels receiving a single photon of 
light as a stimuli will open between 30 and 70% of the time 
and allow for ion flow, changing the membrane potential and 
possibly stimulating an action potential. 
2 
3 
4 
1 
B 
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1- Ultrasound transducer delivers kHz to MHz vibrations 
through the skull which penetrate up to 3 cm. 
2- Pressure fluctuations induced by the ultrasonic vibrations 
will cause the targeted FCLA to enhance sonoluminescence 
phenomena. 
3- Light-sensitive ion channels receiving a single photon of 
light as a stimuli will open between 30 and 70% of the time 
and allow for ion flow, changing the membrane potential and 
possibly stimulating an action potential. 
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